A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients

被引：0
|
作者：
M Gentile
T D Shanafelt
G Cutrona
S Molica
G Tripepi
I Alvarez
F R Mauro
N Di Renzo
F Di Raimondo
I Vincelli
K Todoerti
S Matis
C Musolino
S Fabris
E Vigna
L Levato
S Zupo
F Angrilli
U Consoli
G Festini
G Longo
A Cortelezzi
A Arcari
M Federico
D Mannina
A G Recchia
A Neri
N E Kay
M Ferrarini
F Morabito
机构：
[1] Hematology Unit,Department of Onco
[2] A.O. of Cosenza,hematology
[3] Mayo Clinic,Division of Hematology, Department of Internal Medicine
[4] SS Molecular Diagnostics IRCCS S. Martino-IST,Dipartimento di diagnostica della patologia e delle cure ad alta complessità tecnologica
[5] Pugliese-Ciaccio Hospital,Department of Oncology and Haematology
[6] Consiglio Nazionale delle Ricerche,Division of Haematology, Dipartimento Oncologico e Tecnologie Avanzate
[7] Istituto di Fisiologia Clinica,Divisione di Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia
[8] Arcispedale S. Maria Nuova/IRCCS,Division of Haematology, Department of Biomedical Sciences
[9] Università La Sapienza,Dipartimento di Onco
[10] Hematology Unit,Ematologia
[11] Ospedale Vito Fazzi,Department of Clinical Sciences and Community Health
[12] University of Catania and Ferrarotto Hospital,Department of Hematology
[13] Hematology Unit,Dipartimento ad Attività Integrata Oncologia
[14] A.O. of Reggio Calabria,Dipartimento di Oncologia
[15] Reggio Calabria,Dipartimento di Oncologia ed Ematologia, Department of Onco
[16] Laboratory of Preclinical and Translational Research,Hematology
[17] IRCCS,Department of Onco
[18] Referral Cancer Center of Basilicata,hematology
[19] Direzione Scientifica IRCCS,Divisione di Ematologia
[20] San Martino IST,undefined
[21] Division of Haematology,undefined
[22] Dipartimento di Medicina Interna,undefined
[23] University of Messina,undefined
[24] University of Milano and Hematology CTMO,undefined
[25] Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico,undefined
[26] Ospedale Santo Spirito,undefined
[27] U.O.S. di Emato-Oncologia,undefined
[28] Ospedale Garibaldi-Nesima,undefined
[29] Centro di Riferimento Ematologico-Seconda Medicina,undefined
[30] Azienda Ospedaliero-Universitaria,undefined
[31] Ospedali Riuniti,undefined
[32] Unità di Ematologia,undefined
[33] Ospedale San Vincenzo,undefined
[34] Hematology Unit,undefined
[35] Guglielmo da Saliceto Hospital,undefined
[36] Università di Modena Centro Oncologico Modenese,undefined
[37] Ospedale Papardo,undefined
[38] Biotechnology Research Unit,undefined
[39] Azienda Sanitaria Provinciale di Cosenza,undefined
来源：
Leukemia | 2016年 / 30卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1440 / 1443
页数：3
相关论文
共 50 条
  • [41] Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet Stage A chronic lymphocytic leukemia patients: Results of the multicenter O-CLL1-GISL study
    Gentile, Massimo
    Cutrona, Giovanna
    Mosca, Laura
    Matis, Serena
    Fabris, Sonia
    Lionetti, Marta
    Ilariucci, Fiorella
    Zupo, Simona
    Musolino, Caterina
    Levato, Luciano
    Molica, Stefano
    Di Raimondo, Francesco
    Vincelli, Iolanda
    Di Rienzo, Nicola
    Pesce, Emanuela Anna
    Angrilli, Francesco
    Federico, Massimo
    Neri, Antonino
    Ferrarini, Manlio
    Morabito, Fortunato
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (07) : 743 - 750
  • [42] DECREASED EXPRESSION OF WNT3, A CANONICAL WNT PATHWAY LIGAND, IS FREQUENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PROGRESSION AND IDENTIFIES PATIENTS WITH SHORT TREATMENT-FREE SURVIVAL IN MUTATED IGHV SUBSET
    Poppova, L.
    Janovska, P.
    Plevova, K.
    Radova, L.
    Plesingerova, H.
    Borsky, M.
    Kotaskova, J.
    Kantorova, B.
    Hlozkova, M.
    Figulova, J.
    Brychtova, Y.
    Doubek, M.
    Kozubik, A.
    Pospisilova, S.
    Pavlova, S.
    Bryja, V.
    HAEMATOLOGICA, 2016, 101 : 423 - 424
  • [43] KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival
    Elena Vendramini
    Riccardo Bomben
    Federico Pozzo
    Dania Benedetti
    Tamara Bittolo
    Francesca Maria Rossi
    Michele Dal Bo
    Kari G. Rabe
    Gabriele Pozzato
    Francesco Zaja
    Annalisa Chiarenza
    Francesco Di Raimondo
    Esteban Braggio
    Sameer A. Parikh
    Neil E. Kay
    Tait D. Shanafelt
    Giovanni Del Poeta
    Valter Gattei
    Antonella Zucchetto
    Leukemia, 2019, 33 : 2111 - 2115
  • [44] Surrogate Markers for Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
    Ureshino, Hiroshi
    Kamachi, Kazuharu
    Kimura, Shinya
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (12): : 785 - 790
  • [45] KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival
    Vendramini, Elena
    Bomben, Riccardo
    Pozzo, Federico
    Benedetti, Dania
    Bittolo, Tamara
    Rossi, Francesca Maria
    Dal Bo, Michele
    Rabe, Kari G.
    Pozzato, Gabriele
    Zaja, Francesco
    Chiarenza, Annalisa
    Di Raimondo, Francesco
    Braggio, Esteban
    Parikh, Sameer A.
    Kay, Neil E.
    Shanafelt, Tait D.
    Del Poeta, Giovanni
    Gattei, Valter
    Zucchetto, Antonella
    LEUKEMIA, 2019, 33 (08) : 2111 - 2115
  • [46] COMPARATIVE ANALYSIS OF INTERNATIONAL PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA, PROGRESSION-RISK SCORE AND MD ANDERSON CANCER CENTER 2011 SCORE: REAL WORLD DATA FROM A SINGLE INSTITUTION
    Vukovic, V.
    Antic, D.
    Karan-Djurasevic, T.
    Milic, N.
    Todorovic-Balint, M.
    Bila, J.
    Andjelic, B.
    Djurasinovic, V.
    Sretenovic, A.
    Smiljanic, M.
    Jelicic, J.
    Dencic-Fekete, M.
    Perunicic-Jovanovic, M.
    Kraguljac-Kurtovic, N.
    Pavlovic, S.
    Mihaljevic, B.
    HAEMATOLOGICA, 2017, 102 : 719 - 719
  • [47] High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia
    Hengeveld, Paul
    Kolijn, Pieter M.
    Demmers, Jeroen A. A.
    Doff, Wouter
    Dubois, Julie M. N.
    Rijken, Melissa
    Assmann, Jorn
    Van der Straten, Lina
    Boiten, Henk-Jan
    Gussinklo, Kirsten J.
    Valk, Peter J. M.
    Westerweel, Peter E.
    Kater, Arnon P.
    Langerak, Anton W.
    Levin, Mark-David
    BLOOD, 2022, 140 : 9851 - 9852
  • [48] Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia
    Ureshino, Hiroshi
    Kamachi, Kazuharu
    Kimura, Shinya
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (04): : e138 - e141
  • [49] Alemtuzumab and rituximab for initial treatment of high risk, early stage chronic lymphocytic leukemia (CLL)
    Zent, Clive S.
    Call, Timothy G.
    Shanafelt, Tait D.
    Jelinek, Diane F.
    Tschumper, Renee C.
    Secreto, Charla R.
    Bowen, Deborah A.
    Geyer, Susan M.
    Kabat, Brian F.
    LaPlant, Betsy R.
    Wu, Wenting
    Kay, Neil F.
    BLOOD, 2007, 110 (11) : 611A - 611A
  • [50] Expression levels of Lyn, Syk, PLCγ2 and ERK in patients with chronic lymphocytic leukemia, and higher levels of Lyn are associated with a shorter treatment-free survival
    Wang, Yin-Hua
    Fan, Lei
    Wang, Li
    Zhang, Run
    Zou, Zhi-Jian
    Fang, Cheng
    Zhang, Li-Na
    Li, Jian-Yong
    Xu, Wei
    LEUKEMIA & LYMPHOMA, 2013, 54 (06) : 1165 - 1170
12345